HC Wainwright Has Pessimistic Outlook of ALGS Q1 Earnings

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Aligos Therapeutics in a report issued on Tuesday, March 11th. HC Wainwright analyst E. Arce now expects that the company will post earnings of ($2.37) per share for the quarter, down from their prior estimate of ($1.85). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($10.36) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q2 2025 earnings at ($2.35) EPS, Q3 2025 earnings at ($2.62) EPS, Q4 2025 earnings at $5.91 EPS, FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($8.97) EPS, FY2027 earnings at ($9.99) EPS, FY2028 earnings at ($9.24) EPS and FY2029 earnings at ($9.12) EPS.

Aligos Therapeutics Trading Up 11.3 %

ALGS stock opened at $11.44 on Thursday. The stock has a market cap of $41.05 million, a PE ratio of -0.86 and a beta of 2.52. Aligos Therapeutics has a 12 month low of $6.76 and a 12 month high of $46.80. The company has a 50-day moving average price of $24.25 and a 200 day moving average price of $20.38.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Monday, March 10th. The company reported ($13.08) EPS for the quarter, missing the consensus estimate of ($2.63) by ($10.45). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The firm had revenue of $0.63 million for the quarter, compared to analysts’ expectations of $0.43 million. During the same period in the previous year, the firm earned ($5.50) earnings per share.

Institutional Trading of Aligos Therapeutics

Several institutional investors have recently added to or reduced their stakes in ALGS. Tower Research Capital LLC TRC raised its holdings in shares of Aligos Therapeutics by 2,073.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock worth $26,000 after buying an additional 622 shares during the period. AlphaMark Advisors LLC grew its position in Aligos Therapeutics by 1,000.0% in the 4th quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after acquiring an additional 1,000 shares during the last quarter. Golden State Wealth Management LLC bought a new position in Aligos Therapeutics in the 4th quarter valued at $107,000. Northern Trust Corp purchased a new stake in Aligos Therapeutics in the fourth quarter worth $205,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Aligos Therapeutics by 19.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company’s stock worth $569,000 after purchasing an additional 2,306 shares during the last quarter. Institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).